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a b s t r a c t
Macromolecular nucleic acids such as DNA vaccines, siRNA, and splice-site switching oligomers (SSO)
have vast chemotherapeutic potential. Nanoparticulate biomaterials hold promise for DNA and RNA
delivery when a means for binding is identified that retains structure–function and provides stabilization
by the nanoparticles. In order to provide these benefits of binding, we combined DNA and RNA with
protamineddemonstrating association to gold microparticles by electrophoretic, gel shot, fluorescence,
and dynamic laser light spectroscopy (DLLS). A pivotal finding in these studies is that the Au–protamine–
DNA conjugates greatly stabilize the DNA; and DNA structure and vaccine activity are maintained even
after exposure to physical, chemical, and temperature-accelerated degradation. Specifically, protamine
formed nanoparticles when complexed to RNA. These complexes could be detected by gel shift and were
probed by high throughput absorbance difference spectroscopy (HTADS). Biological activity of these RNA
nanoparticles (RNPs) was demonstrated also by a human tumor cell splice-site switching assay and by
siRNA delivery against B-Rafda key cancer target. Finally, RNA:protamine particles inhibited growth of
cultured human tumor cells and bacteria. These data provide new insights into DNA and RNA nano-
particles and prospects for their delivery and chemotherapeutic activity.
 2009 Elsevier Ltd. All rights reserved.
1. Introduction
Despite the promise of nanotechnology for the delivery of
therapeutic nucleic acids, amajor current limitation is the inability to
combine therapeutic DNA and RNAwith nanomaterials to maintain
structure and function after bioprocessing and delivery. DNA
vaccines [1], siRNA [2], and splice-site switching oligomers (SSO) [3]
may have the ability to modulate gene expression in cells, thereby
creating a new class of molecular chemotherapeutics. Given the
emergent knowledge that alternative splicing plays an important
role in the molecular basis of disease [4], there is an important
impetus for SSO delivery, in particular, because nanoparticles
delivering RNA may be able to elegantly target and correct the
disease at the RNA level.
For binding to nanoparticle supports, the majority of work
reported thus far has focused on DNA, not RNA. Typical modes
of DNA binding involve (1) alkylthiol- or disulfide-terminated
oligonucleotides on a metal nanoparticle surface, (2) covalent
binding of oligonucleotides to a pre-activated nanoparticle surface,
and (3) absorption of biotinylated oligonucleotides on surfaces
coated with avidin or streptavidin [5,6]. Indeed, Seferos et al. [7]
recently demonstrated that such oligoDNA–gold conjugates,
termed ‘‘nanoflares,’’ can specifically detect mRNA. Thiol linkage to
metal nanoparticles takes advantage of the strong coordination
chemistry that exists between somemetals and sulfur. Importantly,
DNA–Au nanoparticles, functionalized with probe strands termi-
nated in a triethylthiol group, were stable at higher temperatures
and in the presence of reducing agents when compared tomono- or
cyclic-dithiane species [5]. Furthermore, DNA–Au nanoparticles
from the trithiol linker had higher DNA-probe surface coverages
than those frommono-thiol or cyclic-dithiane species [6]. However,
it is unclear currently whether or not these strategies can be
applied to macromolecular DNA vaccine, siRNA, or SSO RNA
analogs.
For DNA vaccines, one approach we have patented involves
attaching DNA to the surface of gold microparticles via protamine
for delivery by gene gun [8]. To enhance stability, several groups
have reported that the attachment of proteins to gold nanoparticles
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affords the proteins resistance to temperature and protease
degradation [9,10]. In comparison to proteins, nucleic acids are
considerably more susceptible to chemical and enzymatic degra-
dation. Recently, we reported that protamine mediates attachment
of DNA to gold microparticles and protects the DNA from nuclease
degradation [11]. Herein our aimwas to investigate whether or not
Au–protamine–DNA conjugates enhance chemical stabilization of
DNA aswell; treating them for weeks tomonths against accelerated
physical, chemical, and temperature degradation; and then testing
their vaccine activity in mice.
In addition to its stabilization enhancing properties, protamine
is well known for transporting macromolecules into cells. More
importantly for this work, protamine is known to condense DNA
into nano-structures [12,13] and to deliver antisense oligonucleo-
tides as nanoparticles [14]. Protamine is known, additionally, to
exhibit cell penetrating activity [15,16] and is an important
component of several cancer targeting systems [17,18]. However,
protamine binding to siRNA or SSO RNA, and thus the formation of
RNA:protamine nanoparticles and their delivery, has not been
described to the best of our knowledge. Finally, we investigated the
potential chemotherapeutic utility of these RNA and DNA nano-
particles and their effects on cultured human tumor cell and
microbial cell growth.
2. Materials and methods
2.1. Reagents and bio-molecules
Microparticle gold was obtained from DeGussa or from Bio-Rad. Protamine
(clupeine) and all other reagents were obtained from Sigma–Aldrich. Plasmid DNA
was obtained as previously reported [19]. Oligomer sequences (705 SSO) and siRNA
(see below) were a generous gift from Professor Rudy Juliano, University of North
Carolina-Chapel Hill, Chapel Hill, NC.
2.2. Nano-conjugation
Nanoparticles were prepared on a Cole-Parmer dual head Masterflex C/L (model
#77120-62) pump at a constant rate with microfluidic inner diameter tygon tubing.
Gold particles were included in some batches (3–35 mg batch sizes) mixedmanually
on a vortex at approximately 1 ml/s by first adding protamine (0.01–2 mg/ml) fol-
lowed sequentially by addition of DNA or RNA (0.01–0.1 mg/ml). Thereafter, the
particles were precipitated from 70% ethanol or stored in a 70% ethanol solution
until use. In some cases, nanoparticles were separated by high speed density
gradient centrifugation coupled to light scatter detection (University of North Car-
olina-Chapel Hill, Biophysical Instrumentation Core). Alternatively, nanoparticles
were confirmed by dynamic laser light scatter spectroscopy (DLLS) in the laboratory
of Professor Leaf Huang (University of North Carolina-Chapel Hill, Department of
Molecular Therapeutics) or on a Malvern Zetasizer Nano-ZS90 DLLS from a suspen-
sion of water or phosphate buffered saline.
2.3. Nano-characterization
UV/Vis and fluorescence spectroscopy of the nanoparticles and nucleic acids
were conducted on Thermo Scientific NanoDrop instruments, either a NanoDrop
1000 Spectrophotometer or a NanoDrop 3300 Fluorospectrometer.
2.4. Stabilization
Open circle (OC) DNA standard was generated by treating supercoiled DNAwith
citrate/DMED [20]. Linear (Lin) DNA standard was generated by restriction digestion
with XMa1 following the vendor’s recommended protocol. Both OC and Lin nucleic
acid species were precipitated from ethanol (Spectrum UV grade) (70% alcohol/
water), re-dissolved in 1 Tris/NaCl/EDTA (TNE buffer), and stored frozen until use.
Anion-exchange HPLC chromatography was performed as described by Molloy et al.
[21], except with the employment of a Toso-Haas column and a sodium chloride/
aqueous gradient on a Varian Prostar system with DAD detector. Oxidation was
accomplished in 0.1% H2O2. Two week and one, two, or three month accelerated
degradation treatments were conducted in standard cell culture incubators at 5%
CO2 in the presence of desiccant at room temperature or 40 C or, in some cases,
60 C. Gamma irradiation treatment was executed by standard protocol (Sterigenics,
Inc., NC). For autoclave treatments, particles enclosed in sealed Eppendorf microfuge
tubes were exposed to 30-min sterilization cycles ‘‘dry.’’ Particles (2–3 mg) exposed
to accelerated degradation were then eluted in 1 TNE containing 0.1% SDS for
30 min at 37 C. Ten microliter aliquots were loaded in 1 load buffer (blue juice,
Gibco-BRL) and electrophoresed through 1% agarose gels containing 0.5 mg/ml
ethidium bromide for 45 min at 107 V and 440 mA in a Horizon Life technologies gel
system running in 1 TBE (Gibco-BRL), and the gels were visualized on a gel
documentation station (Syngene, Genetools).
2.5. HeLa 705 splice-site shift assay, siRNA and DNA vaccine biological activity
HeLa 705 cells [22] were seeded into 96-well plates (5000 cells/well) and
allowed to attach overnight. Particles (100 mL), containing 0.1–1 mg/ml protamine
and 150 nM of either 705 sequence [3,22] or anti-B-Raf siRNA sequence (50-
AUGAUCCAGAUCCAAUUCUdTdT-30), were added to the well in a total volume of
200–300 mL Opti-Mem (Gibco-BRL). The medium was removed 6–8 h later, 300 mL
10% FBS/DMEM (without indicator) was added, and the cells were allowed to grow
for an additional 48 h.
Themediumwas then aspirated, the cells washed twicewith PBS buffer and then
cell lysis buffer, luciferase kit reagents were added, and luminescence assayed
(ProMega, Madison, WI). For B-Raf, A375 culturedmelanoma cells were treated with
anti-B-Raf siRNA sequence and B-Raf assayed by western blot according to our
previously published procedure for MDR [23]. DNA vaccine studies were conducted
as previously described [19,25]. Briefly, HBV plasmid (pdp-SC18) was formulated
onto gold particles with a 2 mg pDNA/mg gold target load. Mice were primed with
a single dose of DNA vaccine by gene gun onto the shaved skin on the abdomen
following PowderJect IACUC protocol under the direction of Dr. Lendon Payne. Two
weeks later, bloodwas collected for hepatitis surface and core antigen ELISA. In some
cases, Au–protamine–DNA or Au–spermidine–DNA controls were incubated at 4, 25,
40, or 60 C prior to gene gun administration. Student’s t-test was used for statistical
analysis of the data; statistically significant differences were assumed at p< 0.05.
2.6. Microbiology, cell growth and morphology assays
From a slightly turbid culture of Escherichia coli DH10B grown for approximately
6 h at 30 C, a well-mixed 2 mL aliquot was transferred into a sterile glass tube
containing 60 mL of nanosuspension formed just previously by the 1:1 vol/vol
addition of protamine (5 mg/ml) to tRNA (1 mg/ml) or M9media alone controls. The
suspension of nanoparticles and E. coli cells or controls without nanoparticles were
then brought up to 3 ml total volumewithM9minimal medium, mixed, and either 2
or 20 mL inocula volumes were placed onto sterile LB plates and grown overnight.
Suspension cultures were grown for 5, 30, 60, 120, or 240 min in the presence of
nanoparticles normalized to 10, 3, 1, or 0.3 mg/ml dosages or parallel controls of
protamine, tRNA, or BSA. LB plates were then inoculated, grown overnight, and the
colonies counted. A growth culture was prepared, 200 mL was spread onto an LB
plate, and the plate was allowed to dry in a sterile air flow hood for 10–15 min. A
serial dilution series of tRNA:protamine nanoparticles, tRNA (1 mg/ml), protamine
(5 mg/ml), or BSA (5 mg/ml) controls were spotted in 3 mL spots onto the pre-spread
and dried LB plate and allowed to dry for an additional 15–20 min; subsequently, the
cultures were allowed to incubate overnight. Live/dead cell assaywas performed per
manufacturer’s instructions (Invitrogen Corp.) with Nikon TE2000-E optics coupled
to a Bio-Rad Radiance 2100MP Confocal Laser. HeLa 705 cells were plated onto a 96-
well plate in DMEM with 5% FBS and grown to 80% confluency. These cells were
treated with tRNA (0.1 mg/ml), protamine (1 mg/ml), and the tRNA/protamine
complexes (1:1 v/v). The cells were incubated for 6 h at 37 C. After 6 h, the medium
was removed from the wells. 100 ml of PBS were added to the wells with 100 ml of
Trypan Blue. The cells were mixed and stained for 5–15 min. The stain was removed
from the cells, and the cells were washed with PBS. Images of the cells were taken
using an Olympus 170 inverted brightfield microscope. In some cases, yeast cells
were treated and imaged similarly.
3. Results
3.1. Characterization of DNA binding to gold microparticles
Evidence for DNA attachment to gold is shown in Fig. 1. Particles
were prepared with DNA attached to gold [11,19], and the super-
natant or particle-associated fraction (eluted fromthe particles)was
run by gel electrophoresis (panel A). In comparison to internal load
standards, all five batches appeared to have 25–50 ng of DNA loaded
per 0.5 mgof gold eluted. Particleswere shot into agar gels bya gene
gun in the absence (panel B) or presence (panel C) of ethidium dye
and a non-fluorescence or fluorescence pattern photographed,
revealing the particulate pattern of stained DNA (panel C). Alter-
natively, a series of five sampleswere prepared, and the supernatant
(sup) or particle-associated fractions (part) were assayed by UV or
fluorescence spectroscopy (panel D), indicating a loading efficiency
of greater than 90%. Dynamic laser light scatter (DLLS) showed
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Fig. 1. Plasmid DNA isolated from the supernatant or particle-associated fractions (n¼ 5) were assayed by gel electrophoresis relative to a set of load standards at 10, 25, 50, and
100 ng per lane (panel A). Gene gun delivery of 1 mg DNA-loaded gold into agar gels in the absence (panel B) or presence (panel C) of ethidium incorporation and UV visualization
and photography. Five supernatant (sup) and five particle-associated (part) samples assayed by Hoechst fluorescence for DNA concentration in the nanogram range in comparison to
A260 values (panel D). Dynamic laser light scatter analysis of gold microparticles with spermidine and spermidine–DNA (panel E).
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Fig. 2. Supercoiled DNA at approximately 95% purity was control-degraded with XMaI restriction endonuclease to generate linear forms (lane 2), oxidized in 0.1% H2O2 to generate
a mixture of linear and open circle forms (lane 3), or treated with citrate/DMED [29] to generate stable open circle (lane 4). These samples were used as standards for electrophoresis
or HPLC (upper panel). The lower panel represents four gene gun samples loaded with approximately one microgram of DNA bound onto gold (w1 mg) that were actuated into
buffer, the amount of gold delivered determined by weighing the cartridge afterward, and DNA in the nano-range determined by Hoechst assay [24]. Percent supercoil of the DNA
after expulsion from the gene gun was assayed by capillary, HPLC, and gel electrophoresis, and base line immunogenicity determined in mice by assaying immuno-titer of HBV cAg,
HBV sAg, IFN-gamma, and IL-4 [8,25,26].
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a slight right shift, indicative of larger particles, when DNA was
bound by the standard spermidine approach [8,11,19].
3.2. Characterization of plasmid DNA vaccine delivery
To generate standards, plasmid DNA in solution was degraded
rapidly to open circle and linear forms on a time-scale of seconds to
minutes after exposure to enzyme (lane 2), oxidative (lane 3), or
hydrolytic treatments (lane 4) as shown in Fig. 2A (upper panel).
These degradation products could be base line resolved with
careful analysis by gel or anion-exchange HPLC [31] (Fig. 2A, upper
panel).
Plasmid DNA vaccine encoding Hepatitis B core (cAg) and
surface antigen (sAg) was bound to gold, and delivery was assayed
by loss of gold from the gold cartridge after actuating the gene gun,
and the DNA delivered was assayed by fluorescence spectroscopy
[24], gel or capillary electrophoresis, and HPLC as shown in Fig. 2B
(lower panel). After actuation from the gene gun, the DNA
propelled into buffer retained 50–95% integrity, and when tested in
mice, exhibited robust immunogenicity demonstrated by ELISA
analysis of HBV cAg, HBV sAg, interferon gamma, or interleukin-4 as
standard measures [25,26].
3.3. Stabilization of DNA vaccine by attachment to gold via
protamine
Nucleic acids are susceptible to both chemical and enzymatic
degradation. During the process of preparing conjugates of DNA
attached to microparticle gold, vortex and sonication steps physi-
cally contribute to DNA degradation. Thus (as shown in Fig. 3A),
even untreated DNA, isolated from gold after attachment via
spermidine, has lost a substantial amount of supercoil (shown in
thewells labeled ‘‘U’’). Further conversion from supercoiled to open
circle forms occurs upon exposure of the particles to standard
methods of sterilization, such as gamma irradiation (I) or auto-
claving (A), prior to administration into cell cultures and to animals.
Under these conditions exposure of the powders to higher
temperatures for two weeks, prior to removing the DNA from the
particles and assaying its integrity, accelerates degradation to the
open circle form even though the Au–spermidine–DNA particles
are dried from alcoholdpresumably lessening hydrolysis by
removing water. In contrast, for DNA conjugates prepared by
protamine-ligation to gold, the DNA levels remained relatively
constant after exposure to 25 C or 60 C assayed by Hoechst
binding fluorescence analysis [24] for up to 2–3 months (Fig. 3B).
3.4. Vaccine activity of Au–protamine–DNA exposed to accelerated
degradation
Recently, we reported that attachment of DNA onto gold via
protamine protected the DNA from nuclease degradation, pro-
longing its half-life in plant cell extracts and increasing its
expression level and duration [11]. Maintenance of intact supercoil
type plasmid is a hallmark stability indicator for pharmaceutical
DNA [27]. Conjugation of proteins to nano-gold is similarly known
to protect against proteases and, more importantly, guards against
Fig. 3. Au–spermidine–DNA or Au–protamine–DNA particles, prepared in a 35 mg standard amount [8,25] were vortex-mixed, sonicated and dried from alcohol, and aliquots of the
powders exposed to standard cycles of gamma irradiation (I) and autoclave sterilization (A) as described in the materials and methods; lanes containing untreated DNA are
indicated by ‘‘U’’. The particles were then subjected to exposure at 4 C, 25 C, 40 C, and 60 C (data not shown) for 2 weeks (panel A) or 1, 2, or 3 months (panel B). Afterwards, the
DNA was isolated from 0.5 mg aliquots of the particles with elution buffer and samples were assayed by gel electrophoresis or Hoechst assay as shown above. Supercoiled DNA was
completely lost and open circle band staining intensity diminished for Au–spermidine–DNA as shown by gel; however, more DNA was stained by Hoechst assay for Au–protamine–
DNA at 25 C and 60 C in comparison to Au–spermidine–DNA stored at 4 C (panel B).
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physico-chemical and temperature-accelerated degradation [9,10].
Clearly DNA structure is susceptible to heat, physical, and chemical
degradation as well, which is expected to effect the stability and
activity of DNA vaccines. Notably, as shown above in Fig. 3,
temperature accelerates the physical and chemical degradation and
the bands representing supercoil or open circle forms are lost, or
their fluorescence is greatly diminished.
Here, in contrast and comparison to the above data, protamine
greatly stabilized the DNA attached to gold. Thus, after exposing the
Au-protamine-DNA ternary complexes to a 1, 2, or 3 month
temperature-accelerated forced degradation at 25 C or 60 C, the
DNA retained open circle and, to a lesser extent, supercoil form as
shown by gel analysis (Fig. 4). More importantly, the DNA vaccine
immunogenicity was retained even after exposure to 25 or 60 C for
severalmonths as shown in Fig. 4. Thus, Au–protamine–DNAvaccine
samples, aged for severalmonths at 25 Cor 60 C, retainedHepatitis
B core (cAg) or surface antigen (sAg) activity comparable to
a matched set of Au–spermidine–DNA samples stored at 4 C.
3.5. Delivery of siRNA and SSO without gold and gene gun
Despite its advantages as shown above, gene gun delivery of
nucleic acids supported by microparticle gold has its limitations
[28]. Protamine itself, on the other hand, has membrane trans-
locating activity and is capable of macromolecular transport [15,16].
Further, protamine complexes oligonucleotides to form nano-
particles that have been shown to deliver antisense oligonucleo-
tides into cells [14]. As shown in Fig. 5A, protamine binds RNA,
Fig. 4. Au–spermidine–DNA stored at 4 C or Au–protamine–DNA particles stored at 25 C or 60 C for 1, 2, or 3 months and then administered to mice as aged vaccine. Y-axis
represents immuno-titer of Hepatitis B core antigen ‘‘cAg’’(middle panel) or surface antigen ‘‘sAg’’ (bottom panel) relative to animals treated with control (standard HepB protein
vaccine) [8,25,26]. Protamine samples significantly different than their corresponding matched set of spermidine controls by Student’s t-test statistic are indicated with an asterisk
(p< 0.050). Gel analysis (top panel) of these time and temperature treatments revealed retention of substantial intact supercoiled and open circle DNA forms for several months.
Legend: OC¼ open coil DNA; SC¼ supercoiled DNA; t-0¼ non-degraded sample; con4-1¼ control at 4 C for 1 month; con4-2¼ control at 4 C for 2 months; con4-3¼ control at
4 C for 3 months; Prt25-1¼ protamine at 25 C for 1 month; Prt25-2¼ protamine at 25 C for 2 months; Prt25-3¼ protamine at 25 C for 3 months; Prt60-1¼ protamine at 60 C
for 1 month; Prt60-2¼ protamine at 60 C for 2 months; Prt60-3¼ protamine at 60 C for 3 months.
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producing a gel shift with RNAwhere the complex is retained in the
well. Interestingly, multiple bands were observed in the well,
perhaps indicative of isoforms of protamine [16]. The presence of
amido black, which is known to stain protamine [29] as well as
bromophenol blue and to a lesser extent xylene cyanol, appeared to
impact the staining intensity of the complexes in the wells and
putative RNA:protamine nanoparticles.
To facilitate siRNA entry into cancer cells, investigators have
fused protamine to Fab antibody [17]. Furthermore, LPD nano-
particles containing protamine have been shown to target siRNA to
tumors [18]. Although cancer evolution is complicated, and it is
difficult to identify a specific single gene to target with siRNA-
bearing RNPs, B-Raf and the MEK-Erk pathway it regulates have
received recent attention for their importance as a molecular target
in cancer [30,31]. B-Raf is alternatively spliced [32] and is involved
in the regulation of cell growth, cell-cycle control, and programmed
cell death. Therefore, we reasoned that it was logical to target B-Raf
with RNA-bearing nanoparticles (RNP) bearing anti-B-Raf siRNA,
andwewere able to achieve B-Raf knock-down relative to untreated
cells as shown in Fig. 5B. RNPs were also tested in combinationwith
splice-site switching oligonucleotides (SSO) in the well-described
HeLa tumor cell 705 system; delivery of an SSO overlapping an
aberrant splice-site corrects splicing and switches-on luciferase
[3,22]. Two known SSO sequences, 705 and 623, were compared in
a dose response study, and these data are shown in Fig. 5C. As
recently reported, treatment with the SSO 705 sequence versus the
alternative SSO sequence 623 [33] yielded a higher dose response.
Protamine complexation to RNA forms nanoparticles as detected
directly by dynamic laser light scatter spectroscopy as shown in
Fig. 5D. The RNA:protamine nanoparticles (RNPs) were probed by
chromophoric shift assay in the presence of amido black, bromo-
phenol blue, and xylene cyanol. In each case the presence of the RNP
provided a color change indicative of nanoparticle staining (Fig. 5E).
3.6. Microbial and tumor cell growth inhibition
Consistent with protamine’s well-known membrane traversal
[15,16], the data above suggest that protamine is capable of
Fig. 5. Panel A is a gel shift experiment of RNA:protamine in the presence of amido black, bromophenol blue, and xylene cyanol. Staining of the multiple isoforms of protamine is
shown in lane 4 containing amido black. Staining of the protamine:RNA complex in decreasing quantities of protamine is shown in lanes 5–8 (left to right, 0.5 mg/ml, 0.1 mg/ml,
0.05 mg/ml and 0.03 mg/ml). Lanes 9–12, 13–16, and 17–20 represent a matched set compared to lanes 5–8 with the inclusion of dyes amido black (lanes 9–12), bromophenol blue
(lanes 13–16) or xylene cyanol (lanes 17–20), respectively. Panel B is a western blot of A375 human melanoma cells treated for 48 h with siRNA delivered as a protamine complex
(RNAi lanes) or untreated controls (Con). Inhibition is shown, and Erk is blotted as a comparator. Panel C is a dose response experiment comparing SSO 705 and SSO 623 sequences
for their ability to splice-site switch and up-regulate luciferase expression in the HeLa 705 pLuc system [3,22,33]. Panel D represents protamine–RNA complexes of approximate
50 nm size (n¼ 3 runs), where complexes were formed with vol/vol addition of protamine (1 mg/ml) and tRNA (0.1 mg/ml). Panel E represents chromophoric shift of amido black
(AB), bromophenol blue (BPB) and xylene cyanol (XC) in the absence or presence of RNPs (RNA:protamine nanoparticles).
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conveying RNA into the cells, and that the RNA exhibits functionality
afterwards, either by siRNA activity or splice-site switching. Thus,we
examined next the effect of the RNPs on cell growth and cytotoxicity.
Little growth inhibition and almost no killing were evident for
treatment of HeLa cells with equimolar concentrations of RNPs or
controls (Fig. 6A–C). In marked contrast however, Trypan Blue
viability assays demonstrated approximately 30–40% cell killing,
when these RNPswere incubatedwithyeast, and almost 100%killing
of E. coli as shown by light or fluorescence microscopy (Fig. 6D,E).
Plaque or zone of killing and colony formation assays revealed the
antibacterial activity of the RNPs (Fig. 6F, G). Protamine itself belongs
to a class of cationic antimicrobial peptides [34,35], yet the nano-
particles themselves appear to exhibit antimicrobial properties as
has been shown for other nanoparticles [36,37].
4. Discussion
In summary, we have formed and characterized DNA- and RNA-
based nanoparticles for stabilization and delivery of DNA vaccine,
siRNA, and splice-site switching oligomers (SSOs) targeted towards
cancer and infectious disease. Attachment of DNA vaccine to gold
via protamine appears to stabilize the DNA. These Au–protamine–
DNA conjugates provide the DNA resistance to physico-chemical
and temperature-accelerated degradation and prolong the DNA
vaccine activity. Simple protamine complexed with siRNA and SSO
provide for RNA delivery activity, and these RNA nanoparticles
(RNPs) appear to have differential cell growth and inhibitory effects
on human and microbial cells, thus supporting their chemothera-
peutic potential.
In our studies, attachment of DNA to gold by protamine
enhanced DNA resistance to physico-chemical degradation. Poly
L-lysine (PLL) has been similarly shown to condense and stabilize
plasmid DNA [38]. Interaction of protamine with tRNA was first
reported by X-ray diffraction and circular dichroism [39]; however,
here we use the more novel DLLS and nano-probe UV/Vis
approaches, in addition to gel shift, as a means to confirm these
RNA:protamine nanoparticles. Gold is relatively inert and as such
has been the focus of much work to date; however, other inorganic
nanoparticles may be better substrates for nucleic acid binding
[28,40]. Furthermore, although our nanoparticles are biologically-
based (formed with RNA and protamine), other nanomaterials,
such as iron oxide [41] or silica-based materials [42], may poten-
tially be useful for the binding, stabilization, and delivery of DNA
and RNA.
Protamine is an incorporated component in tumor targeting
[17,18] and is known to facilitate membrane transversal [15,16],
observations that are consistent with the data shown here for
protamine:RNA nanoparticles associatedwith delivery of siRNA and
splice-site switching oligomers (SSO) and up-regulating luciferase
gene expression in the HeLa 705 engineered splicing system.
Furthermore, we show that protamine mediates the plasmid DNA
vaccine attachment to gold microparticles. Recently, a similar
Fig. 6. Panel A shows the effects of lipofectamine, protamine (Hi¼ 1 mg/ml, Lo¼ 0.1 mg/ml), or their complexes with SSO 705 sequence on the number of HeLa cells after a 48-hr
incubation as counted by Coulter counting in a 48 well plate assay. Panels B and C represent comparable treatments of HeLa cells with protamine:RNA complexes at the high or low
levels and stained afterwards with Trypan Blue; dark cells represent dead or dying cells indicating low toxicity. In contrast, Panels D and E represent E. coli bacteria or yeast treated
with RNA:protamine RNPs stained with live/dead fluorescent stain (Invitrogen) or Trypan Blue, respectively, and imaged by light or fluorescence microscopy; yellow or blue cells
reveal dead or dying cells, indicating more overt toxicity for bacteria or yeast. Panel F represents a plaque formation assay wherein cell death was induced by RNP treatment at the
various mass/volume inocula versus protamine, tRNA, or BSA controls. Panel G is a colony formation assay of E. coli colonies counted after treatment with RNPs or controls as
described in the Methods section, demonstrating that colony formation was completely inhibited by protamine:RNA nanoparticles (red line) or partially inhibited by protamine
(green line) versus tRNA-treated bacteria (blue line).
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approach has demonstrated that conjugation of DNA vaccine to
nanoparticle gold by chitosan increases serum antibody titer and
cytotoxic T cell response [26]. Poly-lactide co-glycolide (PLGA)
nanoparticles have been shown to incorporate DNA and increase
uptake intomacrophages [43]; therefore, it may be of some interest
to combine these systems into the nano-range in the near future.
In terms of the biochemical effects of RNPs, we observed that
the dyes in the gel shift, particularly bromophenol blue (BPB),
displace the RNA:protamine complexes. Although this method is
indirect, it constitutes a putatively novel approach for probing
these types of nanoparticles and perhaps others. For example, BPB
and Coomassie Blue can probe hydrophobic sites in proteins [44];
therefore, other chromophoric and fluorometric characterizations
of the RNPs may be possible [45,46].
Biologically, the RNPs appeared to elicit distinctive cytotoxic
effects in bacteria and yeast in comparison to the HeLa cells. In this
case, the RNA:protamine particles were simply formed by
complexation of protamine to transfer RNA (tRNAphe). Neither the
protamine itself nor the tRNA gave these results, suggesting that
there are unique properties of these nanoparticles. RNA processing,
such as splicing, is quite different in eukaryotic versus prokaryotic
organisms. Therefore, it is possible that RNPs bearing RNA mole-
cules designed for RNA-level intervention may exhibit mechanistic
differences that could be crucial for chemotherapeutic selectivity.
5. Conclusions
DNA and RNA nanoparticles may be useful in the binding,
stabilization, and delivery of DNA vaccines, siRNA, and splice-site
switching oligomers. As shown here, one such approach is through
formation of DNA or RNA nanoparticles by complexation of the
nucleic acid with protamine and its ensuing attachment to gold.We
have demonstrated that these Au–protamine–DNA conjugates
greatly resist physico-chemical destruction and retain DNA vaccine
structure and function. In addition to DNA processing, stability, and
delivery advantage, RNA:protamine nanoparticles (RNPs) provide
for delivery of siRNA and inhibit B-Raf, an important cancer target.
The RNPs are capable of delivering splice-site switching oligomers
into human tumor cells, with subsequent up-regulation of lucif-
erase marker gene expression under splice-site switching control.
The RNPs do not appear to inhibit HeLa cell growth significantly, yet
appear to be selectively inhibitory to bacteria and, to a lesser extent,
yeast. These observations imply promising chemotherapeutic
potential.
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Appendix
Figures with essential colour discrimination. Most of the figures
in this article have parts that may be difficult to interpret in black
and white. The full colour images can be found in the on-line
version, at doi:10.1016/j.biomaterials.2009.07.067.
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